<DOC>
	<DOCNO>NCT01616381</DOCNO>
	<brief_summary>This protocol describe 2-arm randomise control pilot study assess tolerance , safety efficacy sildenafil compare control . The hypothesis sildenafil well tolerate efficacious patient chronic heart failure ( NYHA class II III ) evidence systolic dysfunction ( EF â‰¤40 % ) secondary pulmonary hypertension ( SPAP &gt; 40mmHg ) . Patients satisfy inclusion criterion randomize sildenafil ( 40mg x 3 ) placebo therapy 6 month 2:1 blinded fashion . The placebo group compare active therapy group analyse difference main study end-points Patient Global Assessment 6-Minute Walk Test . The study also assess safety , tolerability , symptom quality life .</brief_summary>
	<brief_title>Sildenafil Versus Placebo Chronic Heart Failure</brief_title>
	<detailed_description>It estimate 2-3 % adult population suffers heart failure ( HF ) prevalence increase . The European Society Cardiology ( ESC ) represent country population &gt; 1,1 billion , estimate approximately 30 million patient HF 53 country . Heart failure particularly prevalent elderly population represent major burden patient health service . HF present 10 % patient admitted hospital account ~ 2 % national health expense . Approximately 50 % cost related hospitalisation . Despite optimal non-pharmacological , pharmacological device therapy , morbidity among HF patient high symptom dyspnoea fatigue reduce quality life . Following diagnosis approximately 50 % dead 4 year . Forty percent patient admit hospital HF either dead rehospitalised within one year . During last decade , PDE5-inhibitors evaluate potential treatment heart failure ( see scientific rationale reference ) . However , investigation small still limit data . Trials assess acute effect PDE5-inhibition patient symptomatic HF due systolic dysfunction perform primarily sildenafil . Due short half-life sildenafil drug administer 3 time daily study chronic effect . Previous study evaluate 50 mg dose acutely 50 mg 3 time daily short-term chronic study . Importantly , considerable off-label use sildenafil symptomatic heart failure patient European country . Revatio currently licence pulmonary hypertension group 1 . The dose scheme 20mg x 3 . However , suggest target high dose achieve optimal clinical benefit patient heart failure moderate congestion . As mentioned clinical literature patient symptomatic heart failure do use 50mg x 3 regimen . However , believe propose study use 40mg x 3 equally efficacious . There already considerable experience use dosage scheme heart failure patient locally . The hemodynamic profile PDE-5 inhibitor favourable reduction filling pressure , systemic pulmonary , vascular resistance accompany improvement symptom submaximal peak exercise performance . This pilot study evaluate use PDE5-inhibitor sildenafil patient heart failure , systolic dysfunction document secondary pulmonary hypertension .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Men woman 2 . 18 80 year age . 3 . Outpatients chronic HF . NYHA class IIIII optimal treatment sinus rhythm atrial fibrillation 4 . LVEF &lt; 40 % measure past 12 month 5 . SPAP &gt; 40mmHg use echocardiography 6 . 6MWTD &lt; 400 meter 7 . NTpro BNP &gt; 400 pg/ml BNP &gt; 100 pg/ml , measure past 12 month 8 . Receiving optimal therapy , include diuretic , ACEinhibitor , ARB , betablocker aldosterone antagonist . Doses medication unchanged last 30 day inclusion . 9 . ICDs CRTs ( CRTP , CRTD ) permit . Implantation perform &gt; 3 month inclusion trial . 1 . Acute Coronary Syndrome , include myocardial infarction , coronary angiography , without intervention , within last 3 month 2 . Stroke within last 3 month 3 . Planned coronary angiography plan deviceimplantation 4 . Moderate severe obstructive valve disease 5 . Documented episode sustain ventricular tachycardia 6 . Oral nitrate therapy frequent use sublingual nitrate 7 . Concomitant disease interfere assessment dyspnoea , severe COPD , asthma , restrictive lung disease , severe obesity 8 . Anemia ( hemoglobin &lt; 10g/dL ) 9 . Uncontrolled hypertension ( SBP &gt; 160 mmHg / DBP &gt; 90 mmHg ) 10 . Symptomatic orthostatic hypotension systolic blood pressure &lt; 90 mmHg 11 . Clinically important renal dysfunction ( GFR &lt; 40m ml/min ) 12 . Women childbearing potential 13 . Use ) alpha1 antagonist : doxazosin ii ) CYP3A4 inhibitor : erytromycin , ritonavir , sakinovir , itraconazole , ketoconazole iii ) CYP3A4inducers : rifampicin iv ) Any calcium channel blocker 14 . Retinitis pigmentosa , previous diagnosis NAION ( nonarteritic ischemic opticneuropathy ) , unexplained visual disturbance . 15 . Sickle cell anemia , multiple myeloma , leukemia penile anatomic deformity ( angulation , cavernosal fibrosis , Peyronie ` disease ) increase risk priapism . 16 . Hepatic failure . 17 . Drug alcohol abuse preclude compliance protocol . 18 . Inability understand sign write informed consent form study ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>